Leaps by Bayer | Activity | F4

Leaps by Bayer Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

Investment

Leaps by Bayer led Robigo's Series A financing to advance engineered microbial biopesticides for crop protection. Robigo's ARGO platform uses synthetic biology to engineer microbes that combat fungal diseases in soybeans and specialty crops.

Robigo.bio

Robigo.bio Leaps by Bayer

bayer.com

SEP 17, 2026

SEP 17, 2026

Essay

Juergen Eckhardt published a Forbes op-ed on the pros and cons of full-body MRI screening for early disease detection.

Leaps by Bayer

Leaps by BayerLeaps by Bayer

forbes.comAUG 19, 2026

AUG 19, 2026

Investment

Leaps by Bayer led Sabanto's Series B round. Sabanto provides autonomy retrofit kits for tractors, enabling farmers to deploy autonomous operations without purchasing new expensive machinery.

Sabanto

Sabanto Leaps by Bayer

agfundernews.comJUL 14, 2026

JUL 14, 2026

News

Leaps published its 2025 Annual Review, highlighting $2.1+ billion total invested, 65+ portfolio companies, and 20+ new and follow-on investments in 2025.

Annual Review 2025

Leaps by Bayer

leaps.bayer.com

Added recently

Milestone

Celea Therapeutics dosed the first patient in the global Phase 3 SURPASS-IPF trial evaluating deupirfenidone for idiopathic pulmonary fibrosis.

Celea Therapeutics

Celea Therapeutics Leaps by Bayer

celeatx.comJUL 13, 2026

JUL 13, 2026

Milestone

NuCicer introduced Nuchi, a new class of high-protein chickpeas designed for clean-label food formulation.

NuCicer

NuCicer Leaps by Bayer

leaps.bayer.comJUL 8, 2026

nucicer.com

JUL 8, 2026

Investment

Participated in Celea Therapeutics' $180M financing to advance deupirfenidone as a potential new standard of care for idiopathic pulmonary fibrosis.

Celea Therapeutics

Celea Therapeutics Leaps by Bayer

leaps.bayer.comJUL 2, 2026

businesswire.com

JUL 2, 2026

Essay

Derek Norman, VP of Agriculture Venture Investments at Leaps by Bayer, published a Forbes op-ed on the challenge of growing food in space and the agricultural innovations needed.

Leaps by Bayer

Leaps by BayerLeaps by Bayer

forbes.comJUN 11, 2026

JUN 11, 2026

Investment

Participated in SonoThera's oversubscribed $125M Series B to advance ultrasound-mediated nonviral genetic medicines into clinical development.

SonoThera

SonoThera Leaps by Bayer

leaps.bayer.comJUN 10, 2026

JUN 10, 2026

Investment

Co-led Leaf Agriculture's $13M Series B to bring AI-powered data integration to agribusiness.

Leaf Agriculture

Leaf Agriculture Leaps by Bayer

leaps.bayer.comJUN 10, 2026

JUN 10, 2026

Essay

Juergen Eckhardt published a Forbes op-ed on the FDA approval of the first-ever gene therapy for deafness and what it means for the future of genetic medicine.

Leaps by Bayer

Leaps by BayerLeaps by Bayer

forbes.comMAY 19, 2026

MAY 19, 2026

3 milestones· OCT 2025 – JAN 2026Show all

Milestone

Bayer and Soufflé Therapeutics announced a strategic collaboration to advance cell-specific heart-targeted siRNA therapy.

Soufflé Therapeutics

Soufflé Therapeutics Leaps by Bayer

leaps.bayer.comJAN 8, 2026

JAN 8, 2026

Milestone

Pairwise licensed its CRISPR platform to the International Rice Research Institute to advance climate-resilient, nutritious rice varieties.

Pairwise

Pairwise Leaps by Bayer

leaps.bayer.comNOV 4, 2025

NOV 4, 2025

Milestone

Fork & Good acquired Orbillion to take its cultivated red meat platform global.

Fork & Good

Fork & Good Leaps by Bayer

leaps.bayer.comOCT 30, 2025

OCT 30, 2025

Page 1 of 2